Roche released Phase III trial data on its new multiple sclerosis drug, ocrelizumab, which appears to have an advantage over other MS drugs. It's been shown to treat primary progressive multiple sclerosis (PPMS) the more severe, and previously untreatable, form of the disease. No other drug does this.